

<b>Reference:</b>	FOI.19487.26
<b>Subject:</b>	High-cost drugs in Ophthalmology
<b>Date of Request:</b>	3 February 2026

**Requested:**

1. For the 4 months from September to December 2025, how many unique\* patients received the following intra-vitreal treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab
- Fluocinolone acetonide

\*Please count a patient only once for any treatment, regardless of how many injections or implants they may have received.

**Response:**

Hywel Dda University Health Board (UHB) provides within the table overleaf; the number of unique patients treated with the named treatments during the period 1 September to 31 December 2025.

<b>Treatment</b>	<b>Number</b>
Aflibercept	460
Bevacizumab	0
Brolucizumab	0
Dexamethasone	142
Faricimab	1,410
Ranibizumab	1,148
Fluocinolone acetonide	0